Tempus announced an agreement to distribute Predicta Biosciences’ whole-genome sequencing-based GenoPredicta assay for multiple myeloma. Tempus said GenoPredicta can be used on both peripheral blood and bone marrow to detect actionable DNA alterations, identify high-risk myeloma patients, estimate likelihood of therapy response, and support minimal residual disease monitoring. The assay is positioned as consolidating multiple test modalities—flow cytometry, cytogenetics, and WGS—into a single workflow designed to capture clonal evolution from small tumor-cell input. Tempus emphasized an ultrasensitive, unified approach as part of its broader diagnostics and evidence generation push. For clinicians, the distribution deal expands availability of WGS-enabled risk stratification tools as myeloma care increasingly depends on genomic and MRD readouts.